Matches in Wikidata for { <http://www.wikidata.org/entity/Q91111137> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q91111137 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q91111137 description "scientific article published on 01 April 2019" @default.
- Q91111137 description "wetenschappelijk artikel" @default.
- Q91111137 description "наукова стаття, опублікована 1 квітня 2019" @default.
- Q91111137 name "Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)" @default.
- Q91111137 name "Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)" @default.
- Q91111137 type Item @default.
- Q91111137 label "Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)" @default.
- Q91111137 label "Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)" @default.
- Q91111137 prefLabel "Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)" @default.
- Q91111137 prefLabel "Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)" @default.
- Q91111137 P1433 Q91111137-F378B824-C2F1-44AF-B683-3DD4A67D13A4 @default.
- Q91111137 P1476 Q91111137-43269596-A086-4051-97AF-0B9E45D0A4FE @default.
- Q91111137 P2093 Q91111137-0B5D4746-4BA6-4CF0-87B6-9A81625985D8 @default.
- Q91111137 P2093 Q91111137-1CD20148-B3C2-49D8-B1E4-55178F68191E @default.
- Q91111137 P2093 Q91111137-237B6B33-D5D7-4CB3-997F-DF60AFF06461 @default.
- Q91111137 P2093 Q91111137-23E4C658-8B14-41AE-90EA-91381C78E3CF @default.
- Q91111137 P2093 Q91111137-30990A4F-6A3D-4E1F-A858-B8929F982FA7 @default.
- Q91111137 P2093 Q91111137-32B19C54-5453-4817-ABA3-554099A6D36D @default.
- Q91111137 P2093 Q91111137-5A0C951C-AFC2-44BF-9517-9421AD8BCB4E @default.
- Q91111137 P2093 Q91111137-6EEA598D-76C2-43FC-8C9D-1C1B0BBECC09 @default.
- Q91111137 P2093 Q91111137-759698B4-518A-4B09-A024-311B26E2FA4B @default.
- Q91111137 P2093 Q91111137-7A5C17FA-5B56-44AE-B4CF-644A0E4E5695 @default.
- Q91111137 P2093 Q91111137-840FAC1F-795B-4071-BB3F-EA4013246F24 @default.
- Q91111137 P2093 Q91111137-9EBF1886-DE29-493C-ACDD-409C25CD11E8 @default.
- Q91111137 P2093 Q91111137-BF67E2AE-5C1B-4B79-A62F-88A854F0BE4C @default.
- Q91111137 P2093 Q91111137-D4480540-CD80-4B9F-876B-D975EBD9069B @default.
- Q91111137 P2093 Q91111137-E1F67AD2-832C-4C91-AF04-021122B3B3C6 @default.
- Q91111137 P2093 Q91111137-FB9B2F82-3A3E-4773-83E3-D2920A22A8D8 @default.
- Q91111137 P304 Q91111137-1D729C9D-65CE-4C5A-9C4E-F5E57AE10B51 @default.
- Q91111137 P31 Q91111137-2714E8E1-2666-4369-B27B-D514CDE10D1D @default.
- Q91111137 P356 Q91111137-F714EE2B-A617-44A0-9A33-C4B1B7993832 @default.
- Q91111137 P433 Q91111137-FB940792-6C0C-4A4B-9074-FC54CD508608 @default.
- Q91111137 P478 Q91111137-FB59807C-224D-4820-BCFB-1F0760C7B18F @default.
- Q91111137 P50 Q91111137-EF419497-AFB9-48C7-BF10-856AD7BD5762 @default.
- Q91111137 P577 Q91111137-21060BC8-F776-4316-9667-D0169A2FD02B @default.
- Q91111137 P698 Q91111137-5079F8A6-D7F6-4429-8F2E-AD176A69C3E1 @default.
- Q91111137 P921 Q91111137-98CECFE3-A2B7-4290-A808-021A37356A6F @default.
- Q91111137 P356 MDZ009 @default.
- Q91111137 P698 30657848 @default.
- Q91111137 P1433 Q326122 @default.
- Q91111137 P1476 "Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)" @default.
- Q91111137 P2093 "A Gutierrez" @default.
- Q91111137 P2093 "A P Gonzalez" @default.
- Q91111137 P2093 "A Rodriguez" @default.
- Q91111137 P2093 "A Sureda" @default.
- Q91111137 P2093 "B Sanchez-Gonzalez" @default.
- Q91111137 P2093 "C Martinez" @default.
- Q91111137 P2093 "E Domingo-Domenech" @default.
- Q91111137 P2093 "F de la Cruz" @default.
- Q91111137 P2093 "G Rodriguez" @default.
- Q91111137 P2093 "J L Pinana" @default.
- Q91111137 P2093 "J Lopez" @default.
- Q91111137 P2093 "M Canales" @default.
- Q91111137 P2093 "M D Caballero" @default.
- Q91111137 P2093 "M J Rodriguez-Salazar" @default.
- Q91111137 P2093 "M Moreno" @default.
- Q91111137 P2093 "S Jimenez-Cabrera" @default.
- Q91111137 P304 "612-620" @default.
- Q91111137 P31 Q13442814 @default.
- Q91111137 P356 "10.1093/ANNONC/MDZ009" @default.
- Q91111137 P433 "4" @default.
- Q91111137 P478 "30" @default.
- Q91111137 P50 Q37830539 @default.
- Q91111137 P577 "2019-04-01T00:00:00Z" @default.
- Q91111137 P698 "30657848" @default.
- Q91111137 P921 Q209369 @default.